mufa 18:1-11 t (18:1t n-7)

MUFA 18:1-11 t (18:1t n-7), commonly known as trans-vaccenic acid, is a naturally occurring fatty acid classified as a monounsaturated omega-7 trans fatty acid. Chemically, it is an 18-carbon fatty acid with one double bond in the trans configuration at the 11th carbon position. It is distinguished from industrial trans fats — such as elaidic acid — by its natural origin and metabolic context. Vaccenic acid was first identified in animal fats in the early 20th century and derives its name from the Latin "vacca," meaning cow, reflecting its prominence in ruminant fat and milk fat. In food, vaccenic acid accounts for a significant portion of the trans fats found in dairy and meat from cows, sheep, and goats, typically representing approximately 2–8% of total fat in dairy products and ruminant meat. This contrasts with industrial trans fats from hydrogenated vegetable oils that have well-documented adverse effects on cardiovascular risk. Trans-vaccenic acid is produced biologically in the rumen of ruminant animals through bacterial biohydrogenation of dietary polyunsaturated fats, and it can also be produced endogenously to some extent via the desaturation of certain fatty acid substrates. In nutritional science, it is categorized within the broader class of monounsaturated fatty acids (MUFAs), which are recognized for their role in dietary lipid pools and their metabolic effects on lipid profiles. MUFAs, including vaccenic acid, are components of triglycerides and phospholipids within the body, contributing to cellular membrane structure and energy metabolism. Unlike essential fatty acids such as linoleic acid (an omega-6) and alpha-linolenic acid (an omega-3), vaccenic acid is not considered essential because the body can synthesize MUFAs. However, dietary intake influences circulating levels. Importantly, vaccenic acid differs from industrial trans fatty acids in that it may have neutral or even potentially beneficial effects on lipid metabolism and inflammation in some contexts, although evidence remains mixed and largely observational or from animal models. Its presence in human milk further illustrates its natural occurrence in the diet of breastfed infants and its integration into human lipid metabolism. Overall, MUFA 18:1-11 t is a naturally occurring trans fatty acid found predominantly in ruminant products and participates in complex metabolic and structural lipid networks in the body.

MUFA 18:1-11 t, or trans-vaccenic acid, contributes to human health primarily through its role as a component of dietary fats and as a metabolic precursor to other bioactive lipids. Although specific micronutrient recommendations do not exist for vaccenic acid, scientific evidence suggests that its metabolic fate and effects on lipid profiles differ substantially from industrial trans fats. In particular, natural ruminant trans fatty acids such as vaccenic acid have been studied for their influence on cardiovascular risk markers. In controlled feeding studies and observational research, diets high in natural trans-vaccenic acid have shown mixed effects on lipoprotein profiles, with some studies indicating increases in both LDL and HDL cholesterol concurrently, and a reduction in the LDL/HDL ratio, a key predictor of cardiovascular risk. Trans-vaccenic acid has also been shown to convert via delta-9 desaturase to cis-9, trans-11 conjugated linoleic acid (CLA), another fatty acid with putative health-promoting properties. CLA has been investigated for its potential anti-inflammatory, anti-adipogenic, and immune-modulating effects, although evidence in humans remains inconclusive. Emerging research highlights potential immunological roles for vaccenic acid. A recent study reported that higher circulating levels of vaccenic acid were associated with improved CD8+ T-cell infiltration into tumors and enhanced responsiveness to immunotherapy in oncology settings, suggesting a modulation of anti-tumor immunity. Although preliminary, these findings propose a novel mechanism whereby dietary components of ruminant fats may influence adaptive immune activity and therapeutic outcomes. Beyond immunomodulation, animal studies have linked dietary supplementation with vaccenic acid to decreased triglyceride levels and potential attenuation of hepatic lipid accumulation, indicating effects on systemic lipid metabolism and metabolic health in obesity models. Additionally, cell culture studies have shown that physiological concentrations of vaccenic acid can modulate inflammatory signaling in leukocytes, potentially suppressing pro-inflammatory cytokine production under certain conditions. However, it is critical to emphasize that the evidence base is heterogeneous and sometimes contradictory. While some animal and human studies suggest favorable or neutral outcomes for natural trans-vaccenic acid compared to industrial trans fats, other controlled trials have noted increases in total cholesterol and LDL cholesterol with high intakes of vaccenic acid relative to control diets. Therefore, the health implications of vaccenic acid cannot be isolated from the broader dietary context, total fat intake, and patterns of saturated versus unsaturated fats. Current dietary guidance broadly recommends minimizing trans fats due to their established association with cardiovascular disease, even though natural trans MUFAs like vaccenic acid may have distinct biological effects from industrial trans fats. More research is needed to clarify the specific pathways and health outcomes associated with 18:1-11 t in human populations.

There are no established daily intake recommendations, RDAs, or AIs for MUFA 18:1-11 t (trans-vaccenic acid) from the NIH Office of Dietary Supplements or authoritative nutritional bodies. Instead, public health guidance provides Acceptable Macronutrient Distribution Ranges (AMDRs) for total fat, a category that includes saturated, monounsaturated, and polyunsaturated fats. For adults, total fat should comprise approximately 20–35% of daily caloric intake, with emphasis on unsaturated fats (both monounsaturated and polyunsaturated) as replacements for saturated and industrial trans fats. The absence of a specific RDA reflects the fact that vaccenic acid is a component of dietary fat rather than an essential nutrient that the body cannot synthesize. Consequently, individual requirements for vaccenic acid per se do not exist; rather, its contribution to overall dietary fat is considered in the context of balanced lipid intake. Factors influencing total fat and MUFA needs include age, sex, activity level, metabolic health, and specific health goals. For example, individuals managing dyslipidemia may be advised to adjust the types of fats consumed, favoring cis-configured monounsaturated and polyunsaturated fats while limiting industrial trans fats and excessive saturated fats. Lifestyle and dietary pattern — such as Mediterranean or plant-forward diets — emphasize foods rich in MUFAs like oleic acid, which is the predominant MUFA in human diets. Within these dietary patterns, natural sources of vaccenic acid may be present in moderate amounts from dairy and ruminant meats, but they are not the primary focus of fat quality recommendations. Because of the lack of an established intake level for specific fatty acid isomers like trans-vaccenic acid, dietary guidance prioritizes food sources and overall fat quality. For example, replacing saturated fats with unsaturated fats — including MUFAs — can improve lipid profiles and reduce cardiovascular risk when implemented as part of a healthful diet. However, total transfat intake from all sources, including natural vaccenic acid, should be kept minimal consistent with recommendations to reduce industrial trans fat consumption. Health professionals typically counsel patients to focus on overall dietary patterns rather than specific quantities of individual fatty acid isomers, emphasizing balance, nutrient density, and the replacement of less healthful fats with more healthful unsaturated fats.

Because MUFA 18:1-11 t (trans-vaccenic acid) is not considered an essential nutrient, there is no clinical deficiency syndrome associated with its absence in the diet. Essential fatty acid deficiency is recognized for polyunsaturated fatty acids such as linoleic and alpha-linolenic acids, which cannot be synthesized endogenously and must be obtained from the diet. By contrast, monounsaturated fatty acids are synthesized in the body from saturated fatty acids via desaturase enzymes, and the body does not rely on dietary intake of specific MUFA isomers for normal physiological function. Consequently, a lack of dietary vaccenic acid does not elicit a recognizable deficiency disease. However, the broader category of total monounsaturated fat intake can influence metabolic health. Low intake of unsaturated fats relative to saturated and trans fats has been associated with unfavorable lipid profiles, insulin resistance, and increased cardiovascular risk markers. Symptoms related to an imbalance in dietary fatty acids may manifest indirectly through dyslipidemia, elevated LDL cholesterol, decreased HDL cholesterol, increased triglycerides, and other hallmarks of metabolic syndrome rather than direct signs of deficiency. These manifestations are reflections of overall poor dietary fat quality rather than a specific lack of vaccenic acid itself. At-risk populations for poor fatty acid balance include individuals consuming diets high in processed foods rich in industrial trans fats and saturated fats, and low in unprocessed sources of unsaturated fats such as nuts, seeds, olive oil, and fatty fish. Such patterns may predispose to dyslipidemia and associated conditions such as atherosclerosis and type 2 diabetes. While vaccenic acid itself does not have established deficiency symptoms, this context underscores the importance of balanced fat intake emphasizing healthful MUFAs and PUFAs. Optimal assessment of fatty acid status may involve lipid panels and advanced fatty acid profiling, although these are typically used to evaluate overall cardiovascular risk and not specific to vaccenic acid levels. In summary, absence of dietary vaccenic acid does not cause deficiency diseases, but inadequate unsaturated fat intake overall contributes to metabolic risk profiles that are clinically relevant.

MUFA 18:1-11 t (trans-vaccenic acid) is found predominantly in natural fats from ruminant animals and dairy products. Because it is a component of the fat fraction, foods high in total fat from ruminant sources provide the richest dietary contributions. Examples of food sources with measurable levels of vaccenic acid include beef and lamb fats, veal, dairy products such as butter, cheese, whole milk, and yogurt, as well as other ruminant meat products. The exact amount of vaccenic acid in a given food depends on factors such as the animal’s diet (grass-fed vs grain-fed), breed, and processing methods, but typical contents in milk fat range from approximately 2.7% to 6% of total fatty acids, while ruminant meats can also contain measurable vaccenic acid in the fat portion. Consuming full-fat dairy and marbled cuts of beef or lamb will provide higher amounts of vaccenic acid, whereas lean cuts and low-fat dairy contain lower levels because vaccenic acid is concentrated in the fat component. In addition to traditional meat and dairy sources, human milk also contains vaccenic acid, reflecting its natural presence in mammalian milk lipids. Quantitative amounts vary widely, and specific food databases do not routinely quantify vaccenic acid content separately, but specialized lipid profiling studies and nutrient analysis tools rank foods by their vaccenic acid content. For example, foods such as raw Wagyu beef seam fat and grain-fed chuck short ribs can contain several hundred milligrams of vaccenic acid per 100 g serving, with lower levels in leaner meat cuts. It is important to note that while these foods contain vaccenic acid, dietary recommendations generally prioritize limiting total saturated fat and trans fat intake, focusing instead on healthful unsaturated fat sources such as olive oil, avocados, nuts, and seeds for cardiovascular health. Nonetheless, natural ruminant trans fats like vaccenic acid differ in metabolic effects from industrial trans fats and are part of traditional diets that also include balance of other nutrients. Inclusion of these foods should be part of an overall balanced dietary pattern that meets individual health goals and nutritional needs.

Vaccenic acid, like other long-chain monounsaturated fatty acids, is absorbed in the small intestine similarly to other dietary fats. Upon ingestion, triglycerides containing vaccenic acid are emulsified by bile salts and hydrolyzed by pancreatic lipases into free fatty acids and monoacylglycerols, which are then incorporated into micelles for transport across the enterocyte membrane. Within enterocytes, fatty acids are re-esterified into triglycerides, packaged into chylomicrons, and secreted into the lymphatic system before entering systemic circulation. Because it is a trans configuration fatty acid, vaccenic acid may incorporate into cell membranes and lipoproteins differently than cis-configured MUFAs, affecting membrane fluidity and signaling pathways. Bioavailability of vaccenic acid is influenced by factors such as the overall fat content of the meal, digestive enzyme activity, bile acid availability, and competition with other fatty acids for absorption. Dietary context plays a role: high-fat meals may enhance micelle formation and facilitate absorption, whereas low bile acid states such as cholestatic liver disease may impair fat absorption. Once absorbed, vaccenic acid is transported in lipoprotein particles and can be metabolized by tissues or converted enzymatically to other fatty acids, including cis-9, trans-11 conjugated linoleic acid via delta-9 desaturase. This conversion pathway adds complexity to its metabolic fate and potential biological activities. Because vaccenic acid integrates into total fat pools and lipoproteins, its effects on lipid metabolism and health outcomes depend on interactions with other dietary fats, overall diet quality, and individual metabolic status. Competitive inhibition at desaturase and elongase enzymes, influence on inflammatory mediators, and interplay with cellular lipid handling pathways all contribute to the nuanced bioavailability and physiological impact of this fatty acid.

There are no established supplements specific to MUFA 18:1-11 t (vaccenic acid) because it is not recognized as an essential nutrient and does not have formal intake recommendations. Unlike essential fatty acids (such as omega-3s) for which supplements are commonly used, vaccenic acid is typically consumed as part of whole foods like dairy and ruminant meat. Because nutritional guidance emphasizes food-based sources for fatty acids and balanced dietary patterns, supplementation with a single fatty acid isomers such as vaccenic acid is not recommended for the general population. Focus should instead be on overall dietary quality, including adequate intake of unsaturated fats from healthful sources. In research settings, interventions have examined enriched diets or isolated fatty acid supplementation to assess metabolic effects, but these are not translated into consumer products. Some studies have investigated high vaccenic acid diets in animal models showing potential effects on lipid metabolism, such as reduced triglycerides or altered inflammatory responses, but human evidence remains limited and inconclusive. Use of vaccenic acid supplements could alter lipid profiles, but without clear demonstration of clinical benefit or safety, professional guidelines do not endorse such products. Individuals interested in improving cardiovascular and metabolic health are better served by increasing intake of cis-configured unsaturated fats from plant oils, nuts, seeds, and fatty fish, which have robust evidence supporting favorable effects on cholesterol levels and risk reduction. Supplements containing conjugated linoleic acid (CLA) are marketed for weight management or metabolic health, but evidence varies and potential side effects should be discussed with a healthcare provider. For people with specific health conditions or dietary restrictions, consulting a registered dietitian or physician can help tailor fat intake to individual needs without relying on isolated supplements of a non-essential fatty acid like vaccenic acid.

No tolerable upper intake level (UL) has been established for MUFA 18:1-11 t (trans-vaccenic acid) because it is not an essential nutrient and formal safety thresholds have not been defined. However, trans fatty acids as a class — particularly industrially produced trans fats — are associated with increased cardiovascular disease risk and adverse lipid profiles, and public health guidelines recommend minimizing trans fat intake. Natural trans fats like vaccenic acid are metabolically distinct from industrial trans fats, but they are still categorized under total trans fatty acids on nutrition labels and contribute to trans fat intake. Dietary guidelines generally advise that trans fats constitute as little of total energy intake as possible, often recommending less than 1% of daily energy from trans fats. Because vaccenic acid contributes to total trans fat intake, excessive consumption of high-fat ruminant products could increase total trans fat intake beyond recommended limits, with potential implications for cardiovascular risk. Symptoms of excessive fat intake do not manifest as toxicity per se, but chronically high intake of fats — including saturated and trans fats — contributes to dyslipidemia, atherosclerosis, insulin resistance, and metabolic syndrome. In contrast to industrial trans fats that raise LDL cholesterol and lower HDL cholesterol, natural trans fats like vaccenic acid may increase both LDL and HDL cholesterol levels, leading to uncertain net effects on cardiovascular risk. Because evidence is mixed, public health recommendations do not differentiate between sources of trans fats for labeling and risk reduction. Therefore, even though vaccenic acid may have distinct biological properties, it is prudent to align intake with broader dietary patterns that limit trans fats and prioritize unsaturated fats from plant sources. Clinically, high intake of ruminant fats can contribute to elevated LDL cholesterol, increased adiposity, and metabolic derangements over time, not due to vaccenic acid specifically but due to overall high saturated fat and calorie content. Monitoring of blood lipids and metabolic parameters is important in individuals with high dietary fat intake to detect early signs of dyslipidemia or cardiovascular risk. Healthcare providers typically emphasize moderation of total fat intake, particularly saturated and trans fats, rather than focusing on upper limits for individual fatty acid isomers.

Because MUFA 18:1-11 t (trans-vaccenic acid) is a dietary component of fats rather than a drug or supplement, there are no well-characterized direct drug interactions specific to this fatty acid. However, dietary fat intake can influence the absorption and metabolism of certain medications and nutrients. High-fat meals can alter the bioavailability of lipophilic drugs by affecting gastrointestinal transit, bile secretion, and micelle formation, potentially increasing or decreasing drug absorption. For example, medications with fat-dependent absorption profiles — such as certain antifungals (e.g., itraconazole) and some antiretroviral agents — may have altered pharmacokinetics when taken with high-fat meals. In these cases, the presence of dietary fats including vaccenic acid could contribute to changes in absorption kinetics. In addition, high intake of trans fats and saturated fats may exacerbate dyslipidemia, which can influence the effectiveness of lipid-lowering medications such as statins and fibrates. Although this is not a direct interaction at the molecular level, dietary patterns high in unhealthy fats can counteract therapeutic goals of pharmacologic lipid management, necessitating adjustments in drug therapy or greater emphasis on dietary modification. Conversely, diets rich in healthful unsaturated fats such as oleic acid and omega-3 fatty acids from fish oil are often recommended alongside lipid-lowering medications to improve overall cardiovascular risk profiles. Patients taking anticoagulant medications should also be aware that high-fat meals can influence the absorption of fat-soluble vitamins (A, D, E, K), which can affect coagulation pathways and interact with warfarin therapy. Although vaccenic acid specifically does not interact with warfarin, the overall fat content of the diet can contribute to changes in vitamin K absorption and necessitate monitoring of INR levels. As with any dietary component, individuals on multiple medications or with complex health conditions should discuss dietary patterns with their healthcare provider to ensure optimal drug efficacy and safety.